Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 6/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780480 | 0.76 | MAPK1 (0.41) | MAPK1ALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL6283782 | 0.75 | MAPK1 (0.46) | MAPK1ALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL20210850 | 0.74 | MAPK1 (0.36) | TLR4MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL11013935 | 0.73 | MAPK1 (0.42) | TLR4MAPK1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL11013938 | 0.73 | MAPK1 (0.42) | TLR4MAPK1ALDH1A1CHRM2CHRM1 | |
| SCHEMBL21169562 | 0.70 | HRH3 (0.40) | MAPK1ALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL17679765 | 0.70 | HRH3 (0.40) | MAPK1ALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL11014967 | 0.69 | MAPK1 (0.50) | MAPK1ALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL21465758 | 0.69 | MAPK1 (0.40) | TLR4MAPK1ALDH1A1KMT2ACHRM2 | |
| SCHEMBL16097451 | 0.69 | MAPK1 (0.36) | MAPK1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146043-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | CYCLACEL PHARMACEUTICALS INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12570660-B2 | Process for the preparation of a pyrimidino-diazepine derivative | CYCLACEL PHARMACEUTICALS, INC (GB) | 2026-03-10 | — | — | US | disclosed |
| US-12534466-B2 | Crystalline forms of pyrimidino diazepine derivative | CYCLACEL PHARMACEUTICALS INC. (US) | 2026-01-27 | — | — | US | disclosed |
| CN-115806510-B | Synthesis method of 3-trans-4- (2-hydroxyethyl) cyclohexyl-1, 1-dimethylurea | 成都福柯斯医药技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115806510-A | Synthetic method of 3- (trans) -4- (2-hydroxyethyl) cyclohexyl-1, 1-dimethylurea | 成都福柯斯医药技术有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-20220289755-A1 | PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE | TETHRA BIOSCIENCES INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220281880-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | TETHRA BIOSCIENCES INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4013503-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | Cyclacel Limited (GB) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013502-A1 | PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE | Cyclacel Limited (GB) | 2022-06-22 | — | — | EP | disclosed |
| CN-114269727-A | Process for preparing pyrimido-diazepine derivatives | 西克拉塞尔有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021032958-A1 | PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE | CYCLACEL LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032959-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | CYCLACEL LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-2089368-B1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-2089368-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | ERICKSON SHAWN DAVID | 2008-06-19 | — | — | US | disclosed |
| WO-2008065021-A1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570660-B2 | Process for the preparation of a pyrimidino-diazepine derivative | AZI2, TFPI, GTF2I | TLR4 1772/4885MAPK1 2098/4885ALDH1A1 1477/4885 |
| US-20260146043-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | CTNND1, CCNC, SFN | TLR4 3303/4885MAPK1 2769/4885ALDH1A1 4484/4885 |
| US-12534466-B2 | Crystalline forms of pyrimidino diazepine derivative | PLK1, BUB1, CDC25C | TLR4 4129/4885MAPK1 898/4885ALDH1A1 3362/4885 |
| US-20220281880-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | PDCD5, NLRP3, PDCD1 | TLR4 3879/4885MAPK1 3874/4885ALDH1A1 2979/4885 |
| US-20220289755-A1 | PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE | DHPS, CYP3A5, AZI2 | TLR4 2854/4885MAPK1 1487/4885ALDH1A1 1471/4885 |
| US-20080146636-A1 | For therapy of obesity, hyperphagia, anxiety, depression and related disorders and diseases; cis-(S)-2-(1-{4-[(5-Bromo-indan-2-ylmethyl)-amino]-cyclohexyl}-5-chloro-1H-benzoimidazol-2-yl)-propan-2-ol | GPR119, GIPR, EBP | TLR4 1056/4885MAPK1 2437/4885ALDH1A1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.